Previous 10 | Next 10 |
Neurocrine Biosciences, Inc. (NBIX) Q3 2020 Earnings Conference Call November 9, 2020 16:30 ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry...
Neurocrine Biosciences (NBIX): Q3 Non-GAAP EPS of $0.97 misses by $0.28; GAAP EPS of -$0.62 misses by $0.68.Revenue of $258.5M (+16.4% Y/Y) misses by $24.09M.Total cash and cash equivalents and debt securities available-for-sale of $1,126.1M.FY20 guidance: Combined GAAP R&D and SG&A e...
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results INGREZZA® (valbenazine) Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRx ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkin...
Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close.The consensus EPS Estimate is $1.25 (+123.2% Y/Y) and the consensus Revenue Estimate is $282.59M (+27.2% Y/Y).Over the last 2 years, NBIX has beaten EPS estimates 75% ...
Shares have risen by 15% since my March recommendation, but EV of around $180 million appears cheap contrasted to multiple opportunities in epilepsy that they are pursuing. I provide a recap of our bullish thesis and multiple management presentations. Significant milestone payment...
I will provide background information for my new readers. Readers will see the interim data created since my last article. Near-term binary events that should have major benefits will be outlined. First major drug candidate is scheduled for NDA filing by end of 2020. For...
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments™, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic ...
Spruce Biosciences has filed to raise $75 million in an IPO. The firm is developing treatments for rare endocrine disorders. Early trial results have been impressive and the IPO appears reasonably priced, so is worth a look for long-term hold life science investors. For furt...
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results Conference Call and Webcast Scheduled for Monday, November 9 PR Newswire SAN DIEGO, Oct. 6, 2020 SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Neurocrine ...
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting - ONGENTYS, the First and Only Once-Daily COMT Inhibitor, Led to Greater Reductions in ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...